Savara to Present at the Jefferies London Healthcare Conference
09 November 2023 - 8:05AM
Business Wire
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced that
its management team will participate in a fireside chat at the
Jefferies London Healthcare Conference on November 15, 2023 at
12:00pm GMT/7:00am EST. A live webcast of the fireside chat will be
available on Savara’s website at
www.savarapharma.com/investors/events-presentations/ and will be
archived for 90 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108029896/en/
Savara Inc. IR & PR Anne Erickson
anne.erickson@savarapharma.com (512) 851-1366
Savara (NASDAQ:SVRA)
Historical Stock Chart
From May 2024 to Jun 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Jun 2023 to Jun 2024